photoschmidtWe previously discussed Bristol-Myers Squibb Company (NYSE:BMY) in September 2023, discussing its Loss Of Exclusivity issue with its leading product, Revlimid, leading to a significant decline in annualized sales to $$5.5B in 2023, compared to $$12.82B in 2021. Combined with the inability of its other pipelines to offset the losses in the near term, we had preferred to rate the stock as a Hold then. In this article, we shall discuss why our previous Hold rating has proven to be prudent, with t ...